ADAM9 drives PD-L1 shedding via IL-6 suppression and exploring therapeutic role of Bufalin treatment in hepatocellular carcinoma
Abstract The treatment landscape for advanced hepatocellular carcinoma (HCC) has changed significantly with the recent introduction of immunotherapy, particularly immune checkpoint inhibitors (ICIs), such as those for programmed cell death ligand 1 (PD-L1). However, the heterogeneous response to ICI...
Gardado en:
| Principais autores: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Springer
2025-10-01
|
| Series: | Discover Oncology |
| Assuntos: | |
| Acceso en liña: | https://doi.org/10.1007/s12672-025-03522-y |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|